Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 13.10.2020
Formycon AG
Press Release // October 13, 2020
Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received a grant from the Bavarian Research Foundation for the project "Characterization of ACE2-lgG constructs" amounting to Euro 290,000.
SARS-CoV-2 requires the [ … ]
Mon, 12.10.2020
Formycon AG
Press Release // October 12, 2020
Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
- Increase of the share capital by 1,000,000 shares at an issue price of EUR 25.75 per share
- Use of cash inflow mainly for expansion and further development of own pipeline projects
- Capital measure suppor [ … ]
Mon, 12.10.2020
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // Oct 12, 2020
Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
Munich - The Management Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) resolved yesterday, with the approval of the Sup [ … ]
Thu, 24.09.2020
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 39,00.
Zusammenfassung:
Die Ergebnisse von Formycon für H1/20 lagen nahe an unseren Prognosen. Wie
im Jahr 2019 stammten die Einnahme [ … ]
Wed, 23.09.2020
Formycon AG
Press Release // September 23, 2020
Formycon Announces Half-Year Results for 2020
- Group turnover of Euro 16.5 million corresponds to forecasts
- EBITDA of Euro -0.9 million and half-year result of Euro -1.35 million in line with expectations
- Significant progress in late-stage projects, the expansion and further development of the compan [ … ]
Mon, 24.08.2020
Formycon AG
Press Release // August 24, 2020
Formycon and Bioeq Enroll First Patient in Phase III Study with Aflibercept Biosimilar (FYB203)
- The MAGELLAN-AMD study investigates the comparable efficacy, safety and immunogenicity of Formycon's aflibercept biosimilar candidate FYB203 and the reference product Eylea(R)1 in patients with neovascular age-rel [ … ]